Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cal 216 is a branded generic combination product marketed by Sugen Pharma, primarily in the Indian market. It is formulated as a nutritional supplement to support bone health and address calcium deficiencies. The product typically contains a combination of calcium citrate, vitamin D3 (cholecalciferol), magnesium hydroxide, and zinc sulfate. Calcium citrate provides a bioavailable source of calcium essential for bone mineralization, while vitamin D3 acts as an agonist at the vitamin D receptor (VDR) to enhance intestinal calcium absorption. Magnesium and zinc are included as essential co-factors for bone metabolism and overall physiological support. Cal 216 is commonly indicated for the prevention and treatment of osteoporosis, osteomalacia, and hypocalcemia, and is frequently used as a supplement during pregnancy and lactation to meet increased mineral demands.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cal 216.